Viewing Study NCT04610866


Ignite Creation Date: 2025-12-24 @ 4:28 PM
Ignite Modification Date: 2026-01-01 @ 6:43 PM
Study NCT ID: NCT04610866
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-17
First Post: 2020-10-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Sickle Cell Disease View
None Hemolytic Anemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HbS polymerization View
None pyruvate kinase View
None 2,3- diphosphoglycerate View
None ATP in red blood cells View
None Hemolytic Anemia View